-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the support of favorable policies, China's pharmaceutical industry has continued to innovate and develop, and pharmaceutical companies have been enthusiastic about R&D
.
In the first three quarters of this year, the research and development of local pharmaceutical companies was still "in full swing.
" Over 80% of the A-share listed pharmaceutical companies had increased their total R&D investment in the first three quarters compared with the same period last year
.
From the perspective of total investment, 120 pharmaceutical companies have invested more than 100 million yuan in R&D, exceeding 90 in the same period last year
.
Among them, six companies have invested more than 1 billion yuan in R&D, namely Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Mindray Medical, Junshi Biology, Shanghai Pharmaceuticals, and Kelun Pharmaceuticals
.
The R&D investment of these six pharmaceutical companies in the first three quarters was 4.
142 billion yuan, 2.
414 billion yuan, 1.
629 billion yuan, 1.
423 billion yuan, 1.
367 billion yuan, and 1.
189 billion yuan, an increase of 23.
86%, 28.
55%, and 20.
64 respectively compared with the same period last year.
%, 17.
56%, 31.
38% and 18.
97%
.
Another 69 pharmaceutical companies have invested more than the full year of 2020 in R&D.
Among them, the total R&D investment in the first three quarters of this year was 5,110,600 yuan, which was only 22,800 yuan in the same period last year, and the annual investment was only 50,100 yuan
.
In addition, the total R&D investment in the first three quarters of Yixintang, Guangzheng Ophthalmology, Sharp Aisi, and Oriental Biology has also doubled compared with that of the whole year of last year
.
It is worth mentioning that, like local pharmaceutical companies, multinational pharmaceutical companies have also shown a slight "heating up" in R&D investment
.
Judging from the R&D investment of multinational pharmaceutical companies that have disclosed data in 2021Q3, most multinational companies have increased their R&D investment
.
Among them, GSK's R&D investment in the first three quarters of 2021 increased by 34% year-on-year, mainly used to accelerate the research and development of new drugs in the field of oncology
.
In order to speed up the research and development of new drugs, in addition to increasing R&D investment, GSK also plans to completely divest the consumer health business, and spin off the business by spin-off before the middle of 2022
.
Through this spin-off, GSK will receive 8 billion pounds ($11 billion) in dividends, which will be used to support R&D and transactions in four key therapeutic areas-infectious diseases, AIDS, oncology and immunology
.
In addition, the R&D investment of Johnson & Johnson, Novartis, and Takeda Pharmaceutical has also increased by more than 10% year-on-year
.
In terms of the amount of investment, Johnson & Johnson and BMS Q3 have invested more than US$3 billion in research and development, and the research and development expenses of Merck, Novartis, GSK, Eli Lilly and Sanofi are between US$1 and 2 billion
.
However, the R&D investment of Merck and Gilead has decreased year-on-year
.
Among them, Merck's R&D investment in the first three quarters of 2021 was US$2.
445 billion, accounting for 19% of revenue in the same period
.
In the same period of 2020, Merck invested US$3.
4 billion in research and development
.
Compared with the same period in 2020, in the first three quarters of this year, R&D investment has decreased by 27%
.
In 2020, Merck's investment in drug research and development has surpassed Johnson & Johnson, reaching 13.
6 billion U.
S.
dollars, and most of the funds are mainly used for COVID-related investment
.
The analysis believes that these investments may not have brought Merck's anticipated returns
.
Gilead’s Q3 R&D investment in 2021 was US$1.
109 billion, a year-on-year decrease of 4%
.
The R&D expenditure in the third quarter of the previous year was US$1.
158 billion
.
However, the company's revenue and net profit in Q3 of 2021 have achieved significant growth, and the performance is very good
.
According to the financial report for the third quarter of 2021 released by Gilead Sciences on October 28, the company raised its 2021 full-year performance guidance.
It is expected that the product sales for the full year of 2021 will be between US$26 billion and US$26.
3 billion, compared with 24.
4 billion.
US dollars to 25 billion US dollars
.
.
In the first three quarters of this year, the research and development of local pharmaceutical companies was still "in full swing.
" Over 80% of the A-share listed pharmaceutical companies had increased their total R&D investment in the first three quarters compared with the same period last year
.
From the perspective of total investment, 120 pharmaceutical companies have invested more than 100 million yuan in R&D, exceeding 90 in the same period last year
.
Among them, six companies have invested more than 1 billion yuan in R&D, namely Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Mindray Medical, Junshi Biology, Shanghai Pharmaceuticals, and Kelun Pharmaceuticals
.
The R&D investment of these six pharmaceutical companies in the first three quarters was 4.
142 billion yuan, 2.
414 billion yuan, 1.
629 billion yuan, 1.
423 billion yuan, 1.
367 billion yuan, and 1.
189 billion yuan, an increase of 23.
86%, 28.
55%, and 20.
64 respectively compared with the same period last year.
%, 17.
56%, 31.
38% and 18.
97%
.
Another 69 pharmaceutical companies have invested more than the full year of 2020 in R&D.
Among them, the total R&D investment in the first three quarters of this year was 5,110,600 yuan, which was only 22,800 yuan in the same period last year, and the annual investment was only 50,100 yuan
.
In addition, the total R&D investment in the first three quarters of Yixintang, Guangzheng Ophthalmology, Sharp Aisi, and Oriental Biology has also doubled compared with that of the whole year of last year
.
It is worth mentioning that, like local pharmaceutical companies, multinational pharmaceutical companies have also shown a slight "heating up" in R&D investment
.
Judging from the R&D investment of multinational pharmaceutical companies that have disclosed data in 2021Q3, most multinational companies have increased their R&D investment
.
Among them, GSK's R&D investment in the first three quarters of 2021 increased by 34% year-on-year, mainly used to accelerate the research and development of new drugs in the field of oncology
.
In order to speed up the research and development of new drugs, in addition to increasing R&D investment, GSK also plans to completely divest the consumer health business, and spin off the business by spin-off before the middle of 2022
.
Through this spin-off, GSK will receive 8 billion pounds ($11 billion) in dividends, which will be used to support R&D and transactions in four key therapeutic areas-infectious diseases, AIDS, oncology and immunology
.
In addition, the R&D investment of Johnson & Johnson, Novartis, and Takeda Pharmaceutical has also increased by more than 10% year-on-year
.
In terms of the amount of investment, Johnson & Johnson and BMS Q3 have invested more than US$3 billion in research and development, and the research and development expenses of Merck, Novartis, GSK, Eli Lilly and Sanofi are between US$1 and 2 billion
.
However, the R&D investment of Merck and Gilead has decreased year-on-year
.
Among them, Merck's R&D investment in the first three quarters of 2021 was US$2.
445 billion, accounting for 19% of revenue in the same period
.
In the same period of 2020, Merck invested US$3.
4 billion in research and development
.
Compared with the same period in 2020, in the first three quarters of this year, R&D investment has decreased by 27%
.
In 2020, Merck's investment in drug research and development has surpassed Johnson & Johnson, reaching 13.
6 billion U.
S.
dollars, and most of the funds are mainly used for COVID-related investment
.
The analysis believes that these investments may not have brought Merck's anticipated returns
.
Gilead’s Q3 R&D investment in 2021 was US$1.
109 billion, a year-on-year decrease of 4%
.
The R&D expenditure in the third quarter of the previous year was US$1.
158 billion
.
However, the company's revenue and net profit in Q3 of 2021 have achieved significant growth, and the performance is very good
.
According to the financial report for the third quarter of 2021 released by Gilead Sciences on October 28, the company raised its 2021 full-year performance guidance.
It is expected that the product sales for the full year of 2021 will be between US$26 billion and US$26.
3 billion, compared with 24.
4 billion.
US dollars to 25 billion US dollars
.
